Copenhagen, 2015-11-19 14:44 CET (GLOBE NEWSWIRE) -- 19 November 2015 – Pursuant to the Danish Securities Trading Act, section 28a, Zealand must disclose information on transactions with the company’s shares and related securities by executives and persons/companies closely related to them.
With reference to the above, Zealand announces it has received information on the following transactions for disclosure:
| Name: | Christian Thorkildsen |
| Reason: | Employee elected member of the Board of Directors |
| Issuer: | Zealand Pharma A/S |
| Designation: | Shares |
| ISIN Code: | DK0060257814 |
| Transaction: | Sale of shares |
| Trading Date: | 17 November 2015 |
| Market: | Nasdaq Copenhagen |
| Number: | 20,000 |
| Price: | DKK 147.17 |
| Total value: | DKK 2,943,400.00 |
| Name: | Helle Størum |
| Reason: | Employee elected member of the Board of Directors |
| Issuer: | Zealand Pharma A/S |
| Designation: | Shares |
| ISIN Code: | DK0060257814 |
| Transaction: | Sale of shares |
| Trading Date: | 17 November 2015 |
| Market: | Nasdaq Copenhagen |
| Number: | 1,000 |
| Price: | DKK 150.00 |
| Total value: | DKK 150,000.00 |
●●●●●
For further information, please contact:
Hanne Leth Hillman, Senior Vice President for Investor Relations and Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.
Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is marketed globally outside the US as Lyxumia® by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus®) which is on track for regulatory submission in the US in Q4 2015 and in the European Union in Q1 2016.
The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, ZP4207, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as several preclinical peptide therapeutics.
The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand’s business and activities, please visit: www,zealandpharma.com or follow us on Twitter @ZealandPharma
